EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $9.50, but opened at $10.68. EyePoint Pharmaceuticals shares last traded at $11.70, with a volume of 218,134 shares traded.
Wall Street Analysts Forecast Growth
EYPT has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 price target on shares of EyePoint Pharmaceuticals in a report on Friday. Jefferies Financial Group initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a "buy" rating and a $15.00 price target for the company. Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a "sector outperform" rating and a $18.00 price objective on the stock. JPMorgan Chase & Co. lowered their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an "overweight" rating for the company in a research report on Tuesday, August 13th. Finally, StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Saturday, September 21st. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $29.00.
Read Our Latest Analysis on EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Price Performance
The company's 50-day simple moving average is $8.90 and its 200-day simple moving average is $10.52. The company has a market cap of $648.66 million, a price-to-earnings ratio of -6.87 and a beta of 1.57.
EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.03). EyePoint Pharmaceuticals had a negative return on equity of 43.24% and a negative net margin of 172.29%. The firm had revenue of $9.48 million for the quarter, compared to the consensus estimate of $11.61 million. Equities analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.
Institutional Investors Weigh In On EyePoint Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in EYPT. China Universal Asset Management Co. Ltd. raised its position in shares of EyePoint Pharmaceuticals by 68.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,293 shares of the company's stock worth $82,000 after purchasing an additional 4,172 shares during the period. Cyndeo Wealth Partners LLC acquired a new stake in EyePoint Pharmaceuticals during the 3rd quarter worth about $100,000. Woodstock Corp lifted its stake in EyePoint Pharmaceuticals by 29.1% during the third quarter. Woodstock Corp now owns 71,480 shares of the company's stock valued at $571,000 after buying an additional 16,093 shares in the last quarter. Essex Investment Management Co. LLC boosted its holdings in shares of EyePoint Pharmaceuticals by 234.2% in the third quarter. Essex Investment Management Co. LLC now owns 142,144 shares of the company's stock worth $1,136,000 after buying an additional 99,606 shares during the period. Finally, Fiera Capital Corp raised its position in EyePoint Pharmaceuticals by 0.9% during the second quarter. Fiera Capital Corp now owns 677,038 shares of the company's stock valued at $5,890,000 after buying an additional 5,920 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.
About EyePoint Pharmaceuticals
(
Get Free Report)
EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
See Also
Before you consider EyePoint Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EyePoint Pharmaceuticals wasn't on the list.
While EyePoint Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
